Objectives: Dabigatran, rivaroxaban, apixaban, and edoxaban are nonvitamin K antagonist oral anticoagulants (NOACs) approved for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). Phase-3 clinical trials demonstrated NOACs were as effective as warfarin in the prevention of stroke or systemic embolism and associated with decreased incidences of intracranial bleeding. Additionally, NOACs provide quicker onset of action, simpler dosing, more predictable pharmacokinetic profiles, and decreased food and drug interactions compared with warfarin. Despite the advantages of NOACs, the lack of knowledge may limit their use in clinical practice. Methods: A search was performed on the terms ‘atrial fibrillation' and ‘dabigatran', ‘apixaban', ‘edoxaban', or ‘rivaroxaban' to identify relevant papers; large randomized clinical trials, meta-analyses, and treatment guideline recommendations were given preference. Searches to identify registries, treatment guidelines, and meta-analyses relevant to patient subgroups were also employed. Results: Dosing recommendations, initiation of treatment, and applications in patients who undergo NVAF procedures, have mechanical heart valves, or experience other cardiovascular conditions such as myocardial infarction, previous stroke, and valvular heart disease are summarized. The NOAC-specific reversal approaches are also discussed. Conclusions: Several important factors should be considered regarding the adequate use of NOACs, especially in patients with renal impairment or cardiovascular conditions other than NVAF.

Journal Section:
Editor's choice
Keywords:
Atrial fibrillation, Nonvitamin K, Treatment recommendations, Vitamin K, Anticoagulants
1.
Pradaxa® (package insert): Pradaxa® (dabigatran etexilate mesylate) capsules for oral use. Full prescribing information. Ridgefield, Boehringer Ingelheim Pharmaceuticals, 2015.
2.
Xarelto® (package insert): Xarelto® (rivaroxaban) tablets for oral use. Full prescribing information. Titusville, Janssen Pharmaceuticals, 2015.
3.
Eliquis® (package insert): Eliquis® (apixaban) tablets for oral use. Full prescribing information. Princeton, Bristol-Myers Squibb, 2015.
4.
Savaysa™ (package insert): Savaysa™ (edoxaban) tablets for oral use. Full prescribing information. Parsippany, Daiichi Sankyo, 2015.
5.
Bauer KA: Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program 2013;2013:464-470.
https://doi.org/10.1182/asheducation-2013.1.464
[PubMed]
6.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
[PubMed]
https://doi.org/10.1056/NEJMoa0905561
7.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; Engage AF-TIMI Investigators: Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-2104.
[PubMed]
https://doi.org/10.1056/NEJMoa1310907
8.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; Aristotle Committees Investigators: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
[PubMed]
https://doi.org/10.1056/NEJMoa1107039
9.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
[PubMed]
https://doi.org/10.1056/NEJMoa1009638
10.
Levine MN, Raskob G, Landefeld S, Kearon C: Hemorrhagic complications of anticoagulant treatment. Chest 2001;119:108S-121S.
[PubMed]
https://doi.org/10.1378/chest.119.1_suppl.108S
11.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-2747.
[PubMed]
https://doi.org/10.1093/eurheartj/ehs253
12.
Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P; European Heart Rhythm Association: European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-651.
[PubMed]
https://doi.org/10.1093/europace/eut083
13.
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members: 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:e199-e267.
[PubMed]
https://doi.org/10.1161/CIR.0000000000000040
14.
Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB: Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014;63:2141-2147.
[PubMed]
https://doi.org/10.1016/j.jacc.2014.02.549
15.
Hirsh J, Fuster V, Ansell J, Halperin JL; American Heart Association/American College of Cardiology Foundation: American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003;41:1633-1652.
[PubMed]
https://doi.org/10.1016/S0735-1097(03)00416-9
16.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-962.
[PubMed]
https://doi.org/10.1016/S0140-6736(13)62343-0
17.
Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M: Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 2015;132:194-204.
[PubMed]
https://doi.org/10.1161/CIRCULATIONAHA.114.013267
18.
Lauffenburger JC, Rhoney DH, Farley JF, Gehi AK, Fang G: Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. Pharmacotherapy 2015;35:560-568.
[PubMed]
https://doi.org/10.1002/phar.1597
19.
Maan A, Heist EK, Ruskin JN, Mansour M: Practical issues in the management of novel oral anticoagulants - cardioversion and ablation. J Thorac Dis 2015;7:115-131.
[PubMed]
https://doi.org/10.3978/j.issn.2072-1439.2014.11.35
20.
Xu H, Ruff CT, Giugliano RP, Murphy SA, Nordio F, Patel I, Shi M, Mercuri M, Antman EM, Braunwald E: Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 Trial. J Am Heart Assoc 2016;2016:e002587.
[PubMed]
https://doi.org/10.1161/JAHA.115.002587
21.
Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM: Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-2394.
[PubMed]
https://doi.org/10.1093/eurheartj/ehr342
22.
Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC, Berkowitz SD, Breithardt G, Fox KA, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Singer DE, Patel MR: On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF. Circulation 2015;132:A16914.
23.
Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators: newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-1876.
[PubMed]
https://doi.org/10.1056/NEJMc1007378
24.
Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster JY, Hainaut P, Bruyere O, Dogne JM: Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2014;3:e000515.
[PubMed]
https://doi.org/10.1161/JAHA.113.000515
25.
Loffredo L, Perri L, Violi F: Myocardial infarction and atrial fibrillation: different impact of anti-IIa versus anti-Xa new oral anticoagulants: a meta-analysis of the interventional trials. Int J Cardiol 2015;178:8-9.
[PubMed]
https://doi.org/10.1016/j.ijcard.2014.10.124
26.
Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ: Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012;125:669-676.
[PubMed]
https://doi.org/10.1161/CIRCULATIONAHA.111.055970
27.
Di Cera E: Thrombin as procoagulant and anticoagulant. J Thromb Haemost 2007;5(suppl 1):196-202.
[PubMed]
https://doi.org/10.1111/j.1538-7836.2007.02485.x
28.
Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L; APPRAISE Investigators: Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708.
[PubMed]
https://doi.org/10.1056/NEJMoa1105819
29.
Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van de Werf F, Wallentin L; RE-DEEM Investigators: Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-2789.
[PubMed]
https://doi.org/10.1093/eurheartj/ehr113
30.
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS TIMI Investigators: Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
[PubMed]
https://doi.org/10.1056/NEJMoa1112277
31.
Krantz MJ, Kaul S: The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). J Am Coll Cardiol 2013;62:777-781.
[PubMed]
https://doi.org/10.1016/j.jacc.2013.05.024
32.
Noseworthy PA, Kapa S, Deshmukh AJ, Madhavan M, Van Houten H, Haas LR, Mulpuru SK, McLeod CJ, Asirvatham SJ, Friedman PA, Shah ND, Packer DL: Risk of stroke after catheter ablation versus cardioversion for atrial fibrillation: a propensity-matched study of 24,244 patients. Heart Rhythm 2015;12:1154-1161.
[PubMed]
https://doi.org/10.1016/j.hrthm.2015.02.020
33.
Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ: Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-136.
[PubMed]
https://doi.org/10.1161/CIRCULATIONAHA.110.977546
34.
Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Breithardt G; ROCKET AF Steering Committee Investigators: Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013;61:1998-2006.
[PubMed]
https://doi.org/10.1016/j.jacc.2013.02.025
35.
Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, Mohan P, Garcia D, Bartunek J, Vinereanu D, Husted S, Harjola VP, Rosenqvist M, Alexander JH, Granger CB: Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 2014;63:1082-1087.
[PubMed]
https://doi.org/10.1016/j.jacc.2013.09.062
36.
Dentali F, Botto GL, Gianni M, Ambrosino P, Di Minno MN: Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibrillation: a systematic review and meta-analysis of the literature. Int J Cardiol 2015;185:72-77.
[PubMed]
https://doi.org/10.1016/j.ijcard.2015.03.096
37.
Lip GY, Merino J, Ezekowitz M, Ellenbogen K, Zamoryakhin D, Lanz H, Jin J, Al-Saadi N, Mercuri M, Goette A: A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. Am Heart J 2015;169:597.e5-604.e5.
[PubMed]
https://doi.org/10.1016/j.ahj.2015.02.009
38.
Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH; X-VeRT Investigators: Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014;35:3346-3355.
[PubMed]
https://doi.org/10.1093/eurheartj/ehu367
39.
Pallisgaard JL, Lindhardt TB, Hansen ML, Schjerning AM, Olesen JB, Staerk L, Torp-Pedersen C, Gislason GH: Cardioversion and risk of adverse events with dabigatran versus warfarin - a nationwide cohort study. PLoS One 2015;10:e0141377.
[PubMed]
https://doi.org/10.1371/journal.pone.0141377
40.
Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S; RE-LY Study Group: Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010;9:1157-1163.
[PubMed]
https://doi.org/10.1016/S1474-4422(10)70274-X
41.
Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees Investigators: Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012;11:503-511.
[PubMed]
https://doi.org/10.1016/S1474-4422(12)70092-3
42.
Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W: Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012;11:315-322.
[PubMed]
https://doi.org/10.1016/S1474-4422(12)70042-X
43.
Sardar P, Chatterjee S, Wu WC, Lichstein E, Ghosh J, Aikat S, Mukherjee D: New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS One 2013;8:e77694.
[PubMed]
https://doi.org/10.1371/journal.pone.0077694
44.
Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F; RE-ALIGN Investigators: Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-1214.
[PubMed]
https://doi.org/10.1056/NEJMoa1300615
45.
Yadlapati A, Groh C, Malaisrie SC, Gajjar M, Kruse J, Meyers S, Passman R: Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves. Clin Res Cardiol 2016;105:268-272.
[PubMed]
https://doi.org/10.1007/s00392-015-0919-z
46.
Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH: Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation 2015;132:624-632.
[PubMed]
https://doi.org/10.1161/CIRCULATIONAHA.114.014807
47.
PRAXBIND®: PRAXBIND® (idarucizumab) injection, for intravenous use. Full prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf (accessed February 12, 2016). Ridgefield, Boehringer Ingelheim Pharmaceuticals, 2015.
48.
Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI: Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511-520.
[PubMed]
https://doi.org/10.1056/NEJMoa1502000
49.
Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI: When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2016;14:623-627.
[PubMed]
https://doi.org/10.1111/jth.13227
50.
Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA: Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373:2413-2424.
[PubMed]
https://doi.org/10.1056/NEJMoa1510991
51.
Crowther M, Levy GG, Lu G, Leeds J, Lin J, Pratikhya P, Conley PB, Connolly S, Curnutte JT: A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Blood 2014;124:4269.
52.
Portola Pharmaceuticals completes BLA submission to U.S. Food and Drug Administration for andexanet alfa. http://investors. portola.com/phoenix.zhtml?c=198136&p= irol-newsArticle&ID=2123971(accessed February 12, 2016).
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.